In 2024, the Slovenian Agency for Medicinal Products and Medical Devices (JAZMP) launched a new, free electronic bulletin aimed at informing healthcare professionals about current drug safety topics and important updates in drug information. The bulletin, published up to four times a year, consolidates key notices and updates in one place, providing easy access to relevant information to assist in daily medical practice.

The latest bulletin, released in October 2024, covered the following highlights:

– Metamizole: Measures implemented to reduce the risk of agranulocytosis and its serious consequences.
– Medroxyprogesterone acetate: Recommendations to reduce the risk of meningiomas.
– CAR-T Cell Therapy: Increased risk of T-cell-derived secondary malignancies.
– GLP-1 Receptor Agonists: Guidelines to reduce the risk of aspiration during general anesthesia.
– Glatiramer Acetate: Reports of anaphylactic reactions occurring months or even years after treatment initiation.
– 5-Fluorouracil: Risk of misdiagnosing DPD deficiency in patients with renal impairment.
– Finasteride and Dutasteride: Safety review for these drugs initiated.

With the introduction of the pharmacovigilance bulletin, JAZMP aims to ensure that essential drug safety information is readily available in a format tailored to healthcare professionals’ needs. They hope the bulletin will become a valuable tool for decision-making and enhancing patient safety.